Homoharringtonine Synergized with Gilteritinib Results in the Downregulation of Myeloid Cell Leukemia-1 by Upregulating UBE2L6 in FLT3-ITD-Mutant Acute Myeloid (Leukemia) Cell Lines

Figure 3

The combination of gilteritinib and HHT downregulated Mcl-1 expression via different mechanisms. (a, b)The protein level of FLT3 and p-FLT3 in MV4-11 cells and Molm13 cells was altered by gilteritinib and/or HHT. (c, d) Quantification of (a) and (b). The effect of gilteritinib and/or HHT on the downstream signaling of FLT3 in MV4-11 cells (e) and Molm13 cells (f). (g, h) Quantification of (e) and (f). (i) The mRNA expression of Mcl-1 was measured by qPCR in MV4-11 cells and Molm13 cells treated with HHT and/or gilteritinib at the indicated concentrations for 24 hours. (j) The expression levels of Mcl-1 and GAPDH were analyzed by western blotting in MV4-11 and Molm13 cells treated with HHT and/or MG-132 (10 μM) for four hours. (k, l) Quantification of (j). Each group was compared with the control group. , , and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)